INOVIO Pharmaceuticals, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing was signed March 11, 2016. Inovio is a clinical-stage biopharmaceutical company developing DNA immunotherapies and vaccines with electroporation delivery; it had no approved human products or product-sales revenue.
Key financial metrics
| Metric | FY2015 / year-end | FY2014 / comparison |
|---|---|---|
| Total revenue | $40.6 million | $10.5 million |
| Operating expenses | $74.9 million | $50.0 million |
| Loss from operations | $34.3 million | $39.5 million |
| Net loss attributable to Inovio | $29.2 million; $0.43 basic loss per share | $36.1 million; $0.61 basic loss per share |
| Research and development expense | $57.8 million | $34.1 million |
| Cash and cash equivalents | $57.6 million | $40.5 million |
| Short-term investments | $105.4 million | $53.1 million |
| Working capital | $140.4 million | $84.9 million |
| Total liabilities | $37.9 million | $20.2 million |
Revenue grew 288%, primarily from the MedImmune agreement, Roche-related revenue and government grants. Operating expenses rose 50%, led by higher clinical-trial activity, Ebola grant work, headcount and collaboration-related costs. The operating loss narrowed, but the company remained substantially unprofitable. Product gross margin is not applicable because no products were sold.
Cash flow: operating activities used $12.4 million, investing activities used $54.8 million, and financing activities provided $84.4 million. Investing cash use largely reflected purchases of short-term investments. The company reported no material long-term debt; liabilities were primarily accounts payable and accruals, deferred revenue, warrant liabilities and deferred rent. Cash plus short-term investments totaled approximately $163.0 million at year-end.
Quarterly and other notable items
Fourth-quarter 2015 revenue was $5.9 million and net loss attributable to Inovio was $18.0 million. Third-quarter net income of $5.6 million was not indicative of recurring operating profitability; quarterly results included material gains and losses from changes in the value of affiliated-company investments and warrants.
- In May 2015, Inovio raised approximately $81.9 million net through an offering of 10.925 million common shares.
- The $27.5 million MedImmune upfront payment supported a new exclusive INO-3112 license and collaboration. Inovio recognized $16.0 million of MedImmune revenue in 2015; $13.0 million remained deferred at year-end. MedImmune agreed to fund INO-3112 development, with potential milestone payments of up to $700 million and tiered royalties.
- Roche revenue included recognition of previously deferred amounts and a $3.0 million INO-1800 milestone. Roche returned rights to prostate-cancer candidate INO-5150; the companies continued collaboration on hepatitis B candidate INO-1800.
- A $2.1 million income-tax benefit arose principally from tax accounting related to unrealized gains recorded in other comprehensive income. The company also recorded $2.6 million in gains on its GeneOne investment and a substantial unrealized gain on its PLS investment in other comprehensive income.
- The annual loss attributable to Inovio was $29.2 million, and accumulated deficit was $361.1 million. Management said current cash and short-term investments were sufficient for planned working-capital needs for at least the next 12 months, while noting continued reliance on outside financing and that profitability may never be achieved.
Business outlook, risks and contingencies
Management planned to begin a pivotal Phase III study of VGX-3100 for HPV-related cervical dysplasia in 2016, subject to regulatory alignment and development readiness. Other programs included early-stage cancer and infectious-disease trials, including HIV, hepatitis B, Ebola and MERS. The filing describes development plans, not a revenue or earnings forecast; it provides no clear quantified operating guidance.
- VGX-3100 Phase II results showed lesion regression in 49.5% of treated participants versus 30.6% with placebo, and combined lesion regression and viral clearance in 40.2% versus 14.3%. These are clinical-trial findings, not regulatory approval or demonstrated commercial success.
- Inovio expects substantial ongoing R&D spending and losses. Clinical results may not replicate in later trials; candidates may fail safety, efficacy, manufacturing or regulatory requirements, and timelines may slip.
- Revenue is concentrated: MedImmune represented 40% of 2015 revenue, DARPA 28%, and Roche 27%. Timing of grants, milestones and collaboration work can cause significant revenue fluctuations.
- Access to additional capital, successful partnerships, third-party manufacturing, intellectual-property protection, reimbursement and eventual market acceptance are material uncertainties. Equity financing may dilute shareholders.
- Operating lease obligations totaled $18.5 million, including $1.6 million due within one year. Potential indemnification payments were not quantifiable; the filing reported no applicable legal proceedings.
The independent auditor issued an unqualified opinion on the financial statements and on internal control over financial reporting; management also reported effective disclosure controls and internal controls. Subsequent events included a $500,000 U.S. Army grant and an agreement to acquire Bioject assets for $4.5 million in stock and $1.0 million in cash.
Important facts for investors to verify
- Whether VGX-3100 obtained regulatory alignment and started the planned Phase III program, and how trial design, funding and manufacturing plans developed.
- How much of the MedImmune upfront payment and deferred revenue converts to recognized revenue, and whether collaboration milestones or royalties are ultimately achieved.
- Current cash, investment balances and operating cash burn, including the extent to which reported cash flow reflects financing, investment purchases and working-capital timing.
- Progress and safety or efficacy results across clinical programs, especially whether early-stage findings are confirmed in larger controlled trials.
- Customer and grant concentration, potential dilution from future financing, and the status and valuation of affiliated-company investments.